Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study

Overview of attention for article published in Frontiers in oncology, March 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

reddit: 1 Redditor

Citations

dimensions_citation: 55 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Reddit Dimensions citations

So far, Dimensions has found 55 publications that cite this research output.

55

The most recent citing publications are shown below. View all 55 publications that cite this research output on Dimensions.

Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy

Article in Journal of Chemotherapy (September 2024)

The current status and future of targeted-immune combination for hepatocellular carcinoma

Article in Frontiers in Immunology (August 2024)

The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study

Article in Cancer Management and Research (August 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.